Philip J. Bierman, MD, on DLBCL: Managing Patients at Risk of CNS Involvement and Systemic Disease
Pan Pacific Lymphoma Conference 2018Philip J. Bierman, MD, of the University of Nebraska Medical Center, discusses how to identify and treat the 1% to 2% of patients with diffuse large B-cell lymphoma who have central nervous system involvement as well as systemic sites at the time of diagnosis.
Related Videos
Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy
Susan Blumel, RN, BSN, of the University of Nebraska Medical Center, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, of Stanford Health Center, discuss immunotherapy,...
Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease...
Steven M. Horwitz, MD, on CD 30+ PTCL Subtypes: Treatment Update
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what c...
Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need...
Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations
Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understan...
